Search results for "Adverse event"

showing 10 items of 102 documents

Refining sorafenib therapy: lessons from clinical practice

2015

ABSTRACT  Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symp…

Cancer ResearchSettore SECS-P/06 - Economia ApplicataAntineoplastic AgentAge FactorChild–Pugh Bpostprogression treatmentresponse assessmentdose modificationClinical Trials as TopicLiver Neoplasmsadverse event managementAge FactorsChild-Pugh Bpostprogression treatmenthepatocellular carcinomaGeneral MedicinePrognosisadverse event management; child–Pugh B; dose modification; elderly hepatocellular carcinoma; mRECIST; postprogression treatment; eal-world data; response assessment; sorafenibelderly hepatocellular carcinomaCombined Modality Therapychild–Pugh BClinical PracticeTreatment OutcomeOncologyLiver Neoplasmeal-world dataHepatocellular carcinomaadverse event managementRetreatmentDisease Progressiondose modificationHumanmedicine.drugPhenylurea CompoundNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularDisease ResponsePrognosielderly hepatocellular carcinomaProtein Kinase InhibitorAntineoplastic AgentsmRECISTelderlymRECISTAdverse event management Child–Pugh B dose modification elderly hepatocellular carcinoma mRECIST postprogression treatment real-world data response assessment sorafenibmedicineChild–Pugh BHumansCombined Modality TherapyIntensive care medicineAdverse effectProtein Kinase InhibitorsDose Modificationreal-world databusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationSurgeryreal-world dataresponse assessmentsorafenibbusinessFuture Oncology
researchProduct

Reversibility of Central Nervous System Adverse Events in Course of Art

2022

The purpose of this study is to evaluate the frequency of central nervous system adverse events (CNS-AE) on dolutegravir (DTG) and non-DTG containing ART, and their reversibility, in the observational prospective SCOLTA cohort. Factors associated with CNS-AE were estimated using a Cox proportional-hazards model. 4939 people living with HIV (PLWH) were enrolled in DTG (n = 1179) and non-DTG (n = 3760) cohorts. Sixty-six SNC-AE leading to ART discontinuation were reported, 39/1179 (3.3%) in DTG and 27/3760 (0.7%) in non-DTG cohort. PLWH naïve to ART, with higher CD4 + T count and with psychiatric disorders were more likely to develop a CNS-AE. The risk was lower in non-DTG than DTG-cohort (aH…

Central Nervous SystemAnti-HIV Agentsadverse eventHIVAnti-HIV AgentHIV InfectionsHIV Infections.dolutegravirCD4 Lymphocyte CountProspective StudieInfectious DiseasespsychiatricreversibilityVirologyneurocognitiveHumansProspective StudiesCNSCNS; adverse events; HIV; dolutegravir; reversibility; neurocognitive; psychiatricHumanViruses; Volume 14; Issue 5; Pages: 1028
researchProduct

Dentistry and Drug Adverse Events: Between Responsibilities and Regulations

2022

The purpose of this paper is to renew interest and attention to the medical history, prescription, and/or use of drugs during dental practice. The work analyzes the issue of the use of drugs in dentistry from both a clinical and a medical–legal point of view. The laws governing the matter were also taken into consideration, relating them to the roles of prescriber and user that the dentist can acquire. Analysis of various aspects of this matter demonstrates that it is necessary for dentists to know the drugs and medical substances, their characteristics and properties, related effects, and interactions in order to use them appropriately and adequately. Knowledge of interferences, reac…

Chemical Health and SafetydentistrySettore MED/43 - Medicina LegaleHealth Toxicology and Mutagenesisadverse eventappropriatenedrugmedical–legal assessmentcomplicationtoxicity.Toxicologyerrordentistry; drugs; appropriateness; toxicity; adverse events; errors; complications; medical–legal assessmentToxics; Volume 10; Issue 11; Pages: 671
researchProduct

Childhood adversity and psychosis: a systematic review of bio-psycho-social mediators and moderators.

2020

AbstractThe association between childhood adversity (CA) and psychosis has been extensively investigated in recent years. An increasing body of research has also focused on the mediating or moderating role of biological and psychological mechanisms, as well as other risk factors that might account for the link between CA and psychosis. We conducted a systematic search of the PsychINFO, Embase, Ovid, and Web of Science databases for original articles investigating the role of genetic vulnerabilities, environmental factors, psychological and psychopathological mechanisms in the association between CA and psychosis up to August 2019. We included studies with individuals at different stages of …

Child abuseBiopsychosocial modelMediation (statistics)Psychosisgene-environment correlationchild abuseEffect Modifier Epidemiologic03 medical and health sciences0302 clinical medicineAdverse Childhood ExperiencesmedicineHumanspsychotic experiencesSettore MED/25 - PsichiatriaApplied Psychologymechanismschildhood traumaGene-environment correlationmedicine.diseaseModeration030227 psychiatryPsychiatry and Mental healthMoodAdult Survivors of Child Adverse EventsPsychotic DisordersGene-Environment InteractionmaltreatmentPsychology030217 neurology & neurosurgeryClinical psychologyPsychopathologyPsychological medicine
researchProduct

Childhood Adversities and Adult Headache in Poland and Germany.

2015

Objective Various childhood adversities have been found to be associated with chronic pain in adulthood. However, associations were moderate in most studies, i.e. odds ratios (OR) were between one and two. Method An internet survey was performed in 508 Polish and 500 German subjects. A total of 19 childhood adversities were selected and their associations with headaches explored. Age, gender and country were included as potential confounders, as well as their two-way interaction with the risk factors. Results Two strong risk factors were identified. (1) A combined score for physical and emotional neglect showed an odds ratio (OR) of 2.78 (p < .002) to the frequency of headache in adulthood …

Child abuseMalePhysiologyEconomicsSensory PhysiologySocial Scienceslcsh:MedicineCriminologyPathology and Laboratory MedicinePediatrics0302 clinical medicineSociology030202 anesthesiologyRisk FactorsGermanyOdds RatioMedicine and Health SciencesMicroeconomicsMedicineChild AbuseComputer NetworksChildlcsh:ScienceEmotional neglectmedia_commonMultidisciplinaryHeadachesOrganic CompoundsConfoundingChronic painHeadacheSensory SystemsChemistryAdult Survivors of Child Adverse EventsSomatosensory SystemChild PreschoolPhysical SciencesFemaleCrimeHeadachesmedicine.symptomResearch ArticleAdultmedicine.medical_specialtyComputer and Information Sciencesmedia_common.quotation_subjectNeglect03 medical and health sciencesSigns and SymptomsHumansAdultsPsychiatryMigraineInternetbusiness.industryOrganic Chemistrylcsh:RInfant NewbornChemical CompoundsInfantBiology and Life SciencesPain SensationOdds ratiomedicine.diseaseHealth SurveysHousehold EconomicsMigraineAge GroupsAlcoholsPeople and PlacesPopulation Groupingslcsh:QPolandbusiness030217 neurology & neurosurgeryDemographyNeurosciencePLoS ONE
researchProduct

Clinical predictors of adverse events in a 1 year follow-up study post-PTCA.

2002

Clinical predictors adverse events post-PTCA
researchProduct

The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review wi…

2017

Background Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed psychiatric disorders in childhood. A wide variety of treatments have been used for the management of ADHD. We aimed to compare the efficacy and safety of pharmacological, psychological and complementary and alternative medicine interventions for the treatment of ADHD in children and adolescents. Methods and findings We performed a systematic review with network meta-analyses. Randomised controlled trials (≥ 3 weeks follow-up) were identified from published and unpublished sources through searches in PubMed and the Cochrane Library (up to April 7, 2016). Interventions of interest were pharmacolo…

Complementary TherapiesMaleTrastorns de l'atencióPoison controllcsh:MedicineMathematical and Statistical Techniques0302 clinical medicineBehavior TherapyMedicine and Health SciencesMedicine030212 general & internal medicineChildlcsh:ScienceRandomized Controlled Trials as TopicMultidisciplinaryPharmaceuticsMethylphenidate3. Good healthGuanfacineAntidepressant Drug TherapyNeurologyTolerabilityBehavioral PharmacologyResearch DesignPhysical SciencesFemaleStatistics (Mathematics)Research Articlemedicine.drugNeurological Drug Therapymedicine.medical_specialtyAdolescentClinical Research DesignNeuropsychiatric DisordersResearch and Analysis MethodsPlacebo03 medical and health sciencesDevelopmental NeuroscienceDrug TherapyInternal medicineMental Health and PsychiatryHumansAttention deficit hyperactivity disorderPsiquiatriaStatistical MethodsAdverse effectPsychiatryPharmacologyBehaviorbusiness.industryAtomoxetinelcsh:RCentral Nervous System DepressantsBiology and Life Sciencesmedicine.diseaseAttention Deficit Disorder with HyperactivityNeurodevelopmental DisordersCentral Nervous System StimulantsAdhdlcsh:QAdverse EventsbusinessMental Health TherapiesMathematics030217 neurology & neurosurgeryNeuroscienceMeta-AnalysisPLoS ONE
researchProduct

A questionnaire to collect unintended effects of transcranial magnetic stimulation: A consensus based approach

2022

Transcranial magnetic stimulation (TMS) has been widely used in both clinical and research practice. However, TMS might induce unintended sensations and undesired effects as well as serious adverse effects. To date, no shared forms are available to report such unintended effects. This study aimed at developing a questionnaire enabling reporting of TMS unintended effects. A Delphi procedure was applied which allowed consensus among TMS experts. A steering committee nominated a number of experts to be involved in the Delphi procedure. Three rounds were conducted before reaching a consen-sus. Afterwards, the questionnaire was publicized on the International Federation of Clinical Neurophysiolo…

ConsensusSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaTMS adverse eventsDelphi procedure; Neuromodulation; Non-invasive brain stimulation; Safety; TMS adverse events; TMS secondary effects; Transcranial magnetic stimulationNeuromodulationDelphi procedureTranscranial Magnetic StimulationSensory SystemsNeurologyPhysiology (medical)Surveys and QuestionnairesDelphi procedure; Neuromodulation; Non-invasive brain stimulation; Safety; TMS adverse events; TMS secondary effects; Transcranial magnetic stimulation; Consensus; Humans; Surveys and Questionnaires; Transcranial Magnetic StimulationHumansNeurology (clinical)Non-invasive brain stimulationSafetyTranscranial magnetic stimulationTMS secondary effects
researchProduct

Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of …

2022

Corticosteroids (CSs) are widely used in oncology, presenting several different indications. They are useful for induction of apoptosis in hematological neoplasms, for management of anaphylaxis and cytokine release/hypersensitivity reaction and for the symptomatic treatment of many tumour- and treatment-related complications. If the employment of CSs in the oncological setting results in several benefits for patients and satisfaction for clinicians, on the other hand, many potential adverse events (AEs), both during treatment and after withdrawal of CSs, as well as the duality of the effects of these compounds in oncology, recommend being cautious in clinical practice. To date, several gray…

ConsensusSurvivalTumour responseSettore MED/06 - Oncologia MedicaContraindicationsHematologyMedical OncologyItalyOncologyAdrenal Cortex HormonesDoseAdverse eventsHumansCorticosteroidsIndicationsGlucocorticoidsSocieties MedicalCancer
researchProduct

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease

2019

Background: Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated analysis reports the safety, efficacy, and pharmacokinetics (PK) of the ribavirin-free, direct-acting, antiviral, fixed-dose combination of glecaprevir/pibrentasvir (G/P) in patients with chronic HCV genotype 1-6 infections and compensated liver disease, including patients with chronic kidney disease stages 4 or 5 (CKD 4/5). Methods: Data from 9 Phase II and III clinical trials, assessing the efficacy and safety of G/P treatment for 8-16 weeks, were included. The presence of cirrhosis was determined at screening using a liver …

CyclopropanesLiver CirrhosisMaleAminoisobutyric AcidsPyrrolidinesCirrhosisSustained Virologic Responseadverse eventHepacivirusmedicine.disease_causeGastroenterology0302 clinical medicine030212 general & internal medicinePathologie maladies infectieusesSulfonamidesmedicine.diagnostic_testLiver DiseasesPibrentasvirMicrobiologie et protistologie [entomologiephytoparasitolog.]Infectious DiseasesData Interpretation StatisticalLiver biopsyglecaprevir/pibrentasvirHCVDrug Therapy CombinationFemale030211 gastroenterology & hepatologycompensated cirrhosisMicrobiologie et protistologie [parasitologie hum. et anim.]Microbiology (medical)medicine.medical_specialtyGenotypeProlineLactams MacrocyclicHepatitis C virusAntiviral Agents03 medical and health sciencesLeucineQuinoxalinesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryGlecaprevirHepatitis C Chronicmedicine.diseaseBenzimidazolesMicrobiologie et protistologie [bacteriol.virolog.mycolog.]Transient elastographybusinesschronic kidney diseaseKidney diseaseClinical Infectious Diseases
researchProduct